Sight Sciences Announces CE Mark Approval of the VISCO 360 Viscosurgical System for the Surgical Treatment of Glaucoma

Source: Sight Sciences

Sight Sciences announced that the initial European commercial cases with the CE mark approved »VISCO 360 Viscosurgical System will be presented September 12 during the European Society of Cataract and Refractive Surgeons (ESCRS) meeting in Copenhagen, Denmark. The Glaucoma II Session will be in Hall C4 and Prof. Dr. Körber’s presentation titled, “VISCO 360 Viscosurgical Instrument for Ab Interno Canaloplasty: Technique and First Results” will begin promptly at 09:10.

“The microcatheterization and viscodilation of Schlemm’s canal has been shown to safely and consistently reduce intraocular pressure in adult patients with primary open-angle glaucoma,” Prof. Dr. Norbert Körber, Professor of Ophthalmology at the Augencentrum in Cologne, Germany and the first physician to use the approved VISCO360 system in Europe, said in the news release. “Ab externo canaloplasty has become a gold standard surgical procedure in Germany because of its effectiveness, but it remains an overly complex procedure for many surgeons. The VISCO360 System simplifies canaloplasty and allows for complete access to Schlemm’s canal using an easier, ab interno approach. I look forward to sharing my first experiences with the VISCO360 System in a podium presentation at the upcoming ESCRS meeting.”

The VISCO360 System offers ophthalmologists in the EU a user friendly, clear corneal approach to canaloplasty, a glaucoma procedure with a well established safety and efficacy profile. “Receiving CE mark approval for the VISCO360 System and presenting positive commercial experiences with the device are major milestones for our company and, more importantly, for the treatment of patients with glaucoma,” stated Paul Badawi, Founder and CEO of Sight Sciences. “Canaloplasty has always been safe and effective, but adoption has been limited by the surgical complexity and the steep learning curve of the ab externo approach. We’re pleased that the VISCO360 System is helping physicians across Europe perform canaloplasty in a more straightforward and less invasive manner.”

The VISCO360 System is a fully integrated, single-handed, single-use device specifically designed for an ab interno approach using one single clear corneal incision. The system combines a custom access cannula, a soft and flexible microcatheter with an atraumatic tip, an internal infusion pump and viscoelastic reservoir, and a wheel that controls advancement and retraction of the microcatheter using only a single finger.



Related Content